Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceralasertib, Durvalumab, and Nab-Paclitaxel in Advanced TNBC
NCT05582538Phase 2Recruiting
- Sponsor
- IFOM
- Start
- Dec 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceralasertib in triple-negative breast cancer (TNBC), sponsored by IFOM. Primary endpoint: Progression-Free Survival at 12 months. Started Dec 2022; status: recruiting.
02
Drugs
ceralasertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05582538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582538.